Related Experiment Video
Updated: Feb 17, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Insulin-like growth factor receptor inhibitors: baby or the bathwater?
1Masonic Cancer Center, University of Minnesota420 Delaware Street SE, Minneapolis, MN, USA. yeexx006@umn.edu
Abstract:
The success of targeted therapies for cancer is undisputed; strong preclinical evidence has resulted in the approval of several new agents for cancer treatment. The type I insulin-like growth factor receptor (IGF1R) appeared to be one of these promising new targets. Substantial population and preclinical data have all pointed toward this pathway as an important regulator of tumor cell biology. Although early results from clinical trials that targeted the IGF1R showed some evidence of response, larger randomized phase III trials have not shown clear clinical benefit of targeting this pathway in combination with conventional strategies. These disappointing results have resulted in the discontinuation of several anti-IGF1R programs. However, the conduct of these trials has brought to the forefront several important factors that need to be considered in the conduct of future clinical trials. The need to develop biomarkers, a clearer understanding of insulin receptor function, and defining rational combination regimens all require further consideration. In this commentary, the current state of IGF1R inhibitors in cancer therapy is reviewed.
Insights
Targeting the insulin-like growth factor 1 receptor (IGF1R) in cancer showed early promise but failed in large trials. Future research needs biomarkers and better combination strategies for IGF1R inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted cancer therapies have shown success, with the insulin-like growth factor 1 receptor (IGF1R) pathway identified as a key regulator of tumor cell biology.
- Preclinical data and population studies strongly supported IGF1R as a promising therapeutic target in oncology.
Purpose of the Study:
- To review the current status of IGF1R inhibitors in cancer therapy.
- To discuss factors crucial for future clinical trial design targeting the IGF1R pathway.
Main Methods:
- Review of preclinical and clinical trial data for IGF1R inhibitors.
- Analysis of factors influencing trial outcomes and future research directions.
Main Results:
- Early clinical trials targeting IGF1R demonstrated some response, but larger Phase III trials did not show clear clinical benefit when combined with conventional therapies.
- Disappointing results led to the discontinuation of several anti-IGF1R programs.
Conclusions:
- Despite setbacks, the development of IGF1R inhibitors highlighted the need for robust biomarkers.
- Future research must focus on a clearer understanding of insulin receptor function and the design of rational combination regimens for effective cancer treatment.
More Related Videos
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:28Insulin: The Receptor and Signaling Pathways
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:06Oral Hypoglycemic Agents: Glinides
02:38Mitogens and the Cell Cycle